[go: up one dir, main page]

MX2023012141A - Peptidos inmunogenicos magec2, proteinas de union que reconocen peptidos inmunogenicos magec2, y usos de estos. - Google Patents

Peptidos inmunogenicos magec2, proteinas de union que reconocen peptidos inmunogenicos magec2, y usos de estos.

Info

Publication number
MX2023012141A
MX2023012141A MX2023012141A MX2023012141A MX2023012141A MX 2023012141 A MX2023012141 A MX 2023012141A MX 2023012141 A MX2023012141 A MX 2023012141A MX 2023012141 A MX2023012141 A MX 2023012141A MX 2023012141 A MX2023012141 A MX 2023012141A
Authority
MX
Mexico
Prior art keywords
magec2
immunogenic peptides
binding proteins
proteins recognizing
recognizing
Prior art date
Application number
MX2023012141A
Other languages
English (en)
Inventor
Yifan Wang
Gavin Macbeath
Qikai Xu
Andrew P Ferretti
Original Assignee
Tscan Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tscan Therapeutics Inc filed Critical Tscan Therapeutics Inc
Publication of MX2023012141A publication Critical patent/MX2023012141A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)

Abstract

En la presente se proporcionan péptidos inmunogénicos MAGEC2, proteínas de unión que reconocen péptidos inmunogénicos MAGEC2 y usos de estos.
MX2023012141A 2021-04-14 2022-04-14 Peptidos inmunogenicos magec2, proteinas de union que reconocen peptidos inmunogenicos magec2, y usos de estos. MX2023012141A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163174808P 2021-04-14 2021-04-14
US202263329523P 2022-04-11 2022-04-11
PCT/US2022/024728 WO2022221479A2 (en) 2021-04-14 2022-04-14 Magec2 immunogenic peptides, binding proteins recognizing magec2 immunogenic peptides, and uses thereof

Publications (1)

Publication Number Publication Date
MX2023012141A true MX2023012141A (es) 2023-11-28

Family

ID=83641016

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012141A MX2023012141A (es) 2021-04-14 2022-04-14 Peptidos inmunogenicos magec2, proteinas de union que reconocen peptidos inmunogenicos magec2, y usos de estos.

Country Status (11)

Country Link
US (1) US20240190931A1 (es)
EP (1) EP4323379A2 (es)
JP (1) JP2024515646A (es)
KR (1) KR20240007162A (es)
AU (1) AU2022256469A1 (es)
BR (1) BR112023021162A2 (es)
CA (1) CA3216553A1 (es)
IL (1) IL307601A (es)
MX (1) MX2023012141A (es)
TW (1) TW202304964A (es)
WO (1) WO2022221479A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117820429B (zh) * 2024-01-11 2024-06-18 中国水产科学研究院南海水产研究所 一种具有inos抑制作用的乌鳢源活性肽

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9205144B2 (en) * 2011-06-03 2015-12-08 Dana-Farber Cancer Institute, Inc. Identification of conserved peptide blocks in homologous polypeptides
TWI837109B (zh) * 2017-12-28 2024-04-01 美商磨石生物公司 靶向共有抗原之抗原結合蛋白
TW202000907A (zh) * 2018-05-23 2020-01-01 美商葛利史東腫瘤科技公司 共有抗原
BR112021002826A2 (pt) * 2018-08-16 2021-05-04 Biontech Us Inc. construtos de receptor de célula t e usos dos mesmos
EP3917542A4 (en) * 2019-01-29 2023-03-08 Gritstone bio, Inc. MULTISPECIFIC BINDING PROTEINS

Also Published As

Publication number Publication date
IL307601A (en) 2023-12-01
BR112023021162A2 (pt) 2024-01-16
CA3216553A1 (en) 2022-10-20
TW202304964A (zh) 2023-02-01
US20240190931A1 (en) 2024-06-13
WO2022221479A3 (en) 2022-11-24
KR20240007162A (ko) 2024-01-16
JP2024515646A (ja) 2024-04-10
EP4323379A2 (en) 2024-02-21
AU2022256469A1 (en) 2023-10-12
WO2022221479A2 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
CO2024007212A2 (es) Péptidos inmunogénicos magea1, proteínas de unión que reconocen péptidos inmunogénicos magea1, y usos de estos
MX2020009568A (es) Anticuerpos que se unen a cd39 y sus usos.
CY1122494T1 (el) Πρωτεϊνες συντηξης οι οποιες περιλαμβανουν μια πρωτεϊνη δεσμευσης και ενα πολυπεπτιδιο ιντερλευκινης-15 το οποιο εχει μια μειωμενη συγγενεια για il15ra και θεραπευτικες χρησεις αυτων
GEP20227447B (en) Constructs having sirp-alpha domain or variant thereof
ECSP18095014A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
BR112019018307A2 (pt) Plataforma para identificação de peptídeos imunogênicos baseada em população
EA201991168A1 (ru) Белок, связывающий простатический специфический мембранный антиген
CY1124272T1 (el) Κατασκευασματα παραλλαγης sirp-αλφα και χρησεις αυτων
UY36304A (es) Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes
BR112012005713A2 (pt) vacinas direcionadas a célula langerhans.
CO2025005164A2 (es) Péptidos inmunogénicos prame, proteínas de unión que reconocen los péptidos inmunogénicos prame y usos de los mismos
MX2023012111A (es) Proteinas de union que reconocen el antigeno ha-2 y usos de estas.
BR112016016737A2 (pt) Peptídeos, dispositivos e métodos para detecção de anticorpos contra anaplasma
BR112019001115A2 (pt) proteínas de biofusão como vacinas anti-malária
BR112022022937A2 (pt) Proteínas de fusão estabilizadas de proteína de pico de coronavírus
CL2023000477A1 (es) Proteínas de unión restringidas activadas de forma condicional
BR112022017192A2 (pt) Variantes de transglutaminase
EA201992365A1 (ru) Микрофлюидные диффузионные устройства и системы, а также способы их изготовления и применения
MX2023012141A (es) Peptidos inmunogenicos magec2, proteinas de union que reconocen peptidos inmunogenicos magec2, y usos de estos.
EA202190382A1 (ru) Фармацевтические составы на основе маскированных антител
CL2020002459A1 (es) Variantes de anticuerpo c-terminales
BR112023015050A2 (pt) Anticorpos anti-met e usos dos mesmos
CO2024007117A2 (es) Proteínas de unión que reconocen al antígeno hpv16 e7 y usos de las mismas
MX2023005179A (es) Proteínas de unión que reconocen antígeno ha-1 y usos de las mismas.
EA201892085A1 (ru) Новые белки, полученные из альфа-1-микроглобулина, и их применение